New FDA approval for Swiss pharmaceutical company Sintetica. Couvet production site is ready for the US market.
Sintetica's other production site in Couvet, which has been completely renovated thanks to considerable investments in recent years, has also been approved by the US Food and Drug Administration (FDA).
Sintetica, a Swiss pharmaceutical company specialising in the production of medicines for pain therapy and locoregional anaesthesia, is proud to announce that its production site in Couvet, which was completely renovated thanks to considerable investments, has been inspected and approved by the US Food and Drug Administration (FDA). The complex examination was concluded with no deviations found.
This is an extremely important milestone. On the one hand, it opens the door to direct sales of top-quality drugs on the American market. On the other hand, this recognition is a further step on a path of continuous success that has made the Swiss pharmaceutical company a primary leader in the specialised market of anaesthesia, pain management and intensive care.
"Yet another success that crowns the work done daily with knowledge, dedication and passion by men and women who strongly believe in the mission that defines our corporate identity: to innovate and continuously improve therapies."
With these words, Sintetica's CEO Nicola Caronzolo commented on passing the FDA inspection with flying colours.
Contacts
